CD22 positive

P2, N=20, Recruiting, The First Affiliated Hospital of Soochow University | Not yet recruiting --> Recruiting | Initiation date: Oct 2023 --> Apr 2024

P3, N=310, Suspended, Alliance for Clinical Trials in Oncology | Trial completion date: Aug 2024 --> Aug 2025 | Trial primary completion date: Mar 2024 --> Mar 2025

P=N/A, N=158, Recruiting, Gruppo Italiano Malattie EMatologiche dell'Adulto | Not yet recruiting --> Recruiting

m971-CD28-CD3ζ NK-92 cells efficiently lysed CD22-expressing lymphoma cell lines and produced large amounts of cytokines such as IFN-γ and GM-CSF but a lower level of IL-6 after coculturing with target cells. Based on our results, it is evident that transferring m971-CD28-CD3ζ NK-92 cells could be a promising immunotherapy for B cell lymphoma.

Several ongoing trials in older patients with newly diagnosed ALL have yielded encouraging data with inotuzumab ozogamicin in induction alone and in combination with low-intensity chemotherapy. In this podcast, the authors summarize and highlight some of the recent findings on the use of inotuzumab ozogamicin as induction therapy for older adults with newly diagnosed ALL.

P1, N=52, Active, not recruiting, Stanford University | Trial completion date: Dec 2024 --> Dec 2037

P1/2, N=44, Recruiting, Leland Metheny | Trial completion date: Jun 2025 --> May 2026 | Trial primary completion date: Dec 2023 --> May 2024

P2, N=64, Recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2024 --> Feb 2025 | Trial primary completion date: Feb 2024 --> Feb 2025

P=N/A, N=158, Not yet recruiting, Gruppo Italiano Malattie EMatologiche dell'Adulto | N=250 --> 158 | Trial completion date: Jun 2024 --> Nov 2024 | Initiation date: Nov 2023 --> Feb 2024 | Trial primary completion date: Jun 2024 --> Nov 2024

P1, N=10, Active, not recruiting, Stanford University | Suspended --> Active, not recruiting | N=52 --> 10 | Trial completion date: Aug 2035 --> Sep 2036 | Trial primary completion date: Aug 2025 --> Oct 2023

Combining ADCT-602 + pacritinib was beneficial in ADCT-602-resistant cells. Chidamide increased CD22 expression on B-cell tumor surfaces, increasing ADCT-602 activity. These data support clinical testing of ADCT-602 in R/R B-ALL (NCT03698552) and CD22-positive hematological cancers.

P1, N=52, Active, not recruiting, Stanford University | Recruiting --> Active, not recruiting | N=92 --> 52 | Trial completion date: Sep 2034 --> Dec 2024 | Trial primary completion date: Apr 2023 --> Dec 2024

P1, N=52, Suspended, Stanford University

P1/2, N=24, Recruiting, Shanxi Province Cancer Hospital | Trial completion date: Dec 2023 --> Oct 2025 | Trial primary completion date: Dec 2021 --> Oct 2024

P1, N=19, Completed, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting --> Completed | Trial completion date: Aug 2022 --> Nov 2023 | Trial primary completion date: Aug 2022 --> Nov 2023

All patients received fludarabine (FLU) and cyclophosphamide (CTX) conditioning chemotherapy (FLU 30mg/m 2, d1-3; CTX 500mg/m 2, d1-3) before CAR-T infusions. In summary, CD19/CD22 exhibited a manageable safety but limited antileukemia activity. Our study showed that mixture of CD19 CAR-T and CD22 CAR-T cells infusion is fail to expected to compensate for the treatment of relapsed in r/r ALL and prolonging the leukemia-free survival of patients. The low-efficacy of dual-targeted CAR-T cells may be caused by the CAR19 and CAR22 cells interfere with each other and weaken the CAR-T amplification in vivo.

This would be because the PARP inhibitors were still effective in inhibiting the DNA repair in Reh-IO-R cells where the DNA repair function was not augmented. [Conclusion]The combination of IO with PARP inhibitors synergized the antileukemic effect of IO by inhibiting DNA strand break repair in CD22-positive ALL cell lines and IO-resistant ALL cells, suggesting that these results may contribute to overcoming the IO resistance mechanisms.

P4, N=39, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting

P2, N=100, Recruiting, Pfizer | Trial completion date: Jul 2028 --> Jul 2031

No abstract available

Inotuzumab ozogamicin-based induction followed by age-adapted chemotherapy was well tolerated and resulted in high rates of remission and OS. These data provide a rationale for integrating inotuzumab ozogamicin into first-line regimens for older patients with B-ALL.

P2, N=100, Recruiting, Beijing Tongren Hospital

P2, N=20, Not yet recruiting, The First Affiliated Hospital of Soochow University

A 72-year-old man with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) was treated with dasatinib (week1: 50 mg/day, week2: 70 mg/day, week3-: 100 mg/day) and prednisolone from June 2017...Although the treatment was changed to ponatinib 30 mg/day, he experienced a second relapse in June 2018...Because the patient was still CD22-positive, InO was given again, and the patient achieved CR at the end of the second cycle. We had a case where re-administering InO was effective as a salvage therapy for relapsed/refractory Ph+ALL (r/r Ph+ALL) in an elderly patient.

This study has generated a novel bispecific CAR-T cell that can simultaneously target CD19 or CD22 positive tumor cells, providing a new strategy to address the limitations of single-targeted CAR-T therapy in B-cell tumors (limited response or relapse).

P=N/A, N=250, Not yet recruiting, Gruppo Italiano Malattie EMatologiche dell'Adulto

P1, N=36, Active, not recruiting, University of Virginia | Recruiting --> Active, not recruiting | Trial completion date: Jul 2028 --> Jul 2026 | Trial primary completion date: Jul 2024 --> Jul 2023

P1/2, N=0, Withdrawn, M.D. Anderson Cancer Center | N=30 --> 0 | Trial completion date: Aug 2023 --> Nov 2022 | Not yet recruiting --> Withdrawn | Trial primary completion date: Aug 2023 --> Nov 2022

P1/2, N=44, Recruiting, Leland Metheny | Trial primary completion date: Jun 2023 --> Dec 2023

P=N/A, N=32, Completed, Pfizer | Recruiting --> Completed | N=55 --> 32

P2, N=100, Active, not recruiting, Beijing Boren Hospital | Recruiting --> Active, not recruiting

Side-by-side comparisons indicated that while IS7-CAR killed less rapidly than m971-CAR in vitro, it remains efficient in controlling lymphoma xenograft models in vivo. Thus, IS7-CAR presents a potential alternative candidate for treatment of refractory B-cell malignancies.

P2; Not yet recruiting --> Recruiting | Trial primary completion date: May 2023 --> May 2028

P4, N=102, Completed, Pfizer | Active, not recruiting --> Completed

P1, N=26, Recruiting, Dana-Farber Cancer Institute | Trial primary completion date: Jun 2023 --> Jul 2024

P1, N=24, Completed, University of Washington | Active, not recruiting --> Completed | Trial completion date: Oct 2027 --> Jun 2023

P2, N=100, Recruiting, Pfizer | Not yet recruiting --> Recruiting | Trial completion date: Oct 2027 --> Jun 2028 | Trial primary completion date: Oct 2027 --> Jun 2028

P4, N=102, Active, not recruiting, Pfizer | Trial completion date: Sep 2023 --> Jun 2023

P1/2, N=44, Recruiting, Leland Metheny | Trial completion date: Jun 2023 --> Jun 2025 | Trial primary completion date: Nov 2022 --> Jun 2023

No abstract available

InO induction then blinatumomab consolidation is highly active, tolerable therapy for ND, Ph-, CD22+ B-lineage ALL with durable remissions in the majority of pts. The regimen may be considered for older adults with ND, Ph-,CD22+ B-lineage ALL and a comparator regimen for future studies. Support: U10CA180821, U10CA180882, U10CA180820 https://acknowledgments.alliancefound.org .